QualityStocks News – International Stem Cell Scientists to Present Pre-Clinical Research Results at Gene and Cell …

Results to demonstrate broad application of parthenogenetic stem cells.Scottsdale, AZ (PRWEB) May 16, 2012 QualityStocks would like to highlight International Stem Cell Corporation, a publicly traded company focused on the therapeutic applications of human parthenogenetic stem cells (hpSCs) and the development and commercialization of cell-based research and cosmetic products. ISCO's core …

Original post:
QualityStocks News – International Stem Cell Scientists to Present Pre-Clinical Research Results at Gene and Cell …

Vet undertakes stem cell surgery

Animal stem cell regenerative therapy is the newest service at the Animal Hospital of Tiffin.

“We are the official first site for the therapy in Ohio,” said veterinarian Bob McClung.

The technology uses an adult animal’s stem cells to heal itself.

Veterinarian Mike Brothers performed the surgery Monday on his dog, Tucker, a 2-year-old labrador retriever. It was the second surgery performed at the clinic.

Brothers said his dog’s joint problems are hereditary and he’s had problems since he was a puppy.

“What we’ve been able to do is slow down the arthritis,” Brothers said. The cause of the degeneration will continue, but the fatty tissue removed from the dog can be used for future treatments.

From a piece of fatty tissue of the size removed from Tucker, McClung estimated $3.2 billion stem cells were harvested.

Each injection uses about 90 million cells, so there will be enough of the material for future treatments.

“We have basically 2 billion cells to bank,” he said. “We use cryo-preservation.”

In the freezing process, the cells are gradually cooled to prevent damage and stored in liquid nitrogen at temperatures of minus 80 to minus 90 degrees Fahrenheit.

Follow this link:
Vet undertakes stem cell surgery

Lenalidomide prolongs disease control for multiple myeloma patients after stem cell transplant

Public release date: 15-May-2012 [ | E-mail | Share ]

Contact: Elisa Williams willieli@ohsu.edu 503-494-4530 Oregon Health & Science University

PORTLAND, Ore. Multiple myeloma patients are better equipped to halt progression of this blood cancer if treated with lenalidomide, or Revlimid, following a stem cell transplant, according to a study co-authored by a physician with the Oregon Health & Science University Knight Cancer Institute.

The study, published in the New England Journal of Medicine, found a 63 percent reduction in the risk of progressive myeloma or death for the stem cell transplant patients that were treated with lenalidomide maintenance therapy.

“These results add to the evidence that the combination of standard therapies such as stem cell transplantation with the emerging biologic therapies, like lenalidomide, have extended the lives of multiple myeloma patients,” said Richard Maziarz, M.D., of the OHSU Knight Cancer Institute who was one of the study’s co-authors. Maziarz serves as medical director of the Adult Stem Cell Transplantation Program & Center for Hematologic Malignancies at the OHSU Knight Cancer Institute. “We know that for at least three years following a transplant that maintenance therapy with this drug vastly improves the chances that the cancer won’t come back and worsen.”

These data were supported by similar Phase III studies reported from France and Italy in the same issue of the New England Jounal of Medicine demonstrating that maintenance therapy after stem cell transplantation was associated with improved disease control.

Multiple myeloma is a cancer that affects plasma cells, a type of white blood cell normally responsible for producing antibodies. In patients impacted by multiple myeloma, collections of abnormal plasma cells accumulate in the bone marrow, interfering with the production of normal blood cells. The study focused on patients who received an autologous hematopoietic cell transplant (AHCT). AHCT procedures use patients’ own blood stem cells.

While lenalidomide increased a patient’s ability to stave off progression of the disease, questions remain regarding future approaches recognizing that quality of life measurements were not incorporated within these studies, that long-term safety issues remain unclear as there was a small but discernable risk of second cancers observed in the treated patients. In addition to the need for that cost-benefit analysis, a comparison remains to be performed with other emerging myeloma maintenance therapies.

This Phase III study of lenalidomide was conducted at 47 medical centers and involved 568 patients. It was sponsored by the National Cancer Institute (NCI). Revlimid’s manufacturer, Celgene Corp., provided the NCI with lenalidomide for this research.

###

Visit link:
Lenalidomide prolongs disease control for multiple myeloma patients after stem cell transplant

Stem cell banking firms to deploy marketing initiatives to boost sales

Kolkata, May 15:

Stem cell banking companies are looking at aggressive marketing initiatives to move into the mass market segment. Direct marketing to customers and reduction in price tag for storing umbilical cord blood are on the cards.

The umbilical cord blood and cord tissue are one of the richest sources of stem cells and have potential to treat over 75 serious ailments.

The average cost for storing these for a period of 21 years ranges between Rs 75,000 and Rs 90,000 in India.

According to Chennai-based Life Cell, high price points and lack of proper marketing have limited the penetration of cord blood banking in India. Affordability is the key factor in India.

Only when the prices come down will we see more customers opting for the service. We are working on it (bringing down prices), Mr Mayur Abhaya Srisrimal, Executive Director Life Cell, told Business Line.

Stem cell bankers have already rolled out easy finance options such as EMIs to make the services attractive. CordLife, for instance, offers EMI facility for 12-24 months.

This has helped boost our sales. We have been acquiring 350-400 clients each month, said Managing Director, Mr Meghnath Roy Chowdhury.

Finance, however, is not the only stumbling block. Cord blood bankers have, so far, been depending largely on hospital network for signing up clients. Bangalore-based Ms Deepa Shankar, who is expecting and is due for delivery in June, recently opted for Life Cell services through the hospital.

It’s not a sustainable approach. We need to get into direct marketing for pushing up volumes growth, Mr Srisrimal points out. To strike a cord with the would-be mothers, the company has roped in Lisa Ray as brand ambassador. Ms Ray was cured of multiple myeloma courtesy stem cell therapy.

Continue reading here:
Stem cell banking firms to deploy marketing initiatives to boost sales

Stem cell therapy to treat a chimp's torn ACL may prove beneficial for humans

Veterinarians hope a new medical procedure can treat a 25-year-old chimpanzee with a torn ACL, or anterior cruciate ligament, at the “Save the Chimps” in Florida.

The procedure involves injecting the chimp with her own stem cells.

“With chimps we don’t want to do a lot of surgical work, put hardware in their knee, they tend to pull out that sort of thing,” said Veterinarian Linda Gregard, M.D.

Dr. Darrell Nazareth with the Florida Veterinary League has been using stem cells to treat dogs with arthritis for the past two years, but this is his first chimp.

“We’re not using embryonic stem cells, we’re not taking embryos and taking their stem cells from there. We’re just using the patient’s own tissue,” said Dr. Nazareth.

The technology harnesses the bodies own ability to heal itself and doctors hope it could find wider use in humans.

After injecting two billion stem cells into Angie’s knee, doctors will find out in the next two to three weeks if the stem cell therapy treatment was successful.

More here:
Stem cell therapy to treat a chimp's torn ACL may prove beneficial for humans

International Stem Cell Corporation Scientists to Present Pre-Clinical Research Results at American Society of Gene …

CARLSBAD, Calif.–(BUSINESS WIRE)–

International Stem Cell Corporation (OTCBB: ISCO.OB – News) (www.internationalstemcell.com) today announced that several of its leading scientists will present experimental results from three of ISCOs pre-clinical therapeutic programs.

Firstly, the application of A9 dopaminergic neurons derived from human parthenogenetic stem cells (hpSC) for the treatment of Parkinsons disease. Demonstrating functional dopaminergic neurons in vivo represents an important milestone towards the goal of creating well characterized populations of cells that could be used to develop a treatment for Parkinsons.

Secondly, the differentiation of hpSC and embryonic stem cells into cornea-like constructs for use in transplantation therapy and the in vitro study of ocular drug absorption. There are approximately ten million people worldwide who are blind as a result of damage to their cornea. Generating human corneas from a pluripotent stem cell source should increase the likelihood that people will receive treatment in the future even in the absence of suitable tissue from eye banks.

Lastly, the in vivo and in vitro characterization of immature hepatocyte derived from hpSC. Such cells could be used to develop a treatment for individuals with a liver that has been damaged by disease or sufferers of genetic disorders that inhibit normal liver function. In both cases, implanting healthy hepatocyte cells could treat the underlying disease and prolong the life of the individual.

These results not only show the progress we have made in these important programs, but also demonstrate the broad application of human parthenogenetic stem cells in the development of treatments for incurable diseases, says Dr. Ruslan Semechkin, Vice President of Research and Development.

The presentations will take place at the 15th Annual Meeting of American Society of Gene and Cell Therapy, in Philadelphia at 3:30 p.m. on Thursday, May 17th.

About International Stem Cell Corporation

International Stem Cell Corporation is focused on the therapeutic applications of human parthenogenetic stem cells (hpSCs) and the development and commercialization of cell-based research and cosmetic products. ISCO’s core technology, parthenogenesis, results in the creation of pluripotent human stem cells from unfertilized oocytes (eggs). hpSCs avoid ethical issues associated with the use or destruction of viable human embryos. ISCO scientists have created the first parthenogenic, homozygous stem cell line that can be a source of therapeutic cells for hundreds of millions of individuals of differing genders, ages and racial background with minimal immune rejection after transplantation. hpSCs offer the potential to create the first true stem cell bank, UniStemCell. ISCO also produces and markets specialized cells and growth media for therapeutic research worldwide through its subsidiary Lifeline Cell Technology (www.lifelinecelltech.com), and stem cell-based skin care products through its subsidiary Lifeline Skin Care (www.lifelineskincare.com). More information is available at www.internationalstemcell.com or follow us on Twitter @intlstemcell.

To receive ongoing corporate communications, please click on the following link: http://www.b2i.us/irpass.asp?BzID=1468&to=ea&s=0

See the article here:
International Stem Cell Corporation Scientists to Present Pre-Clinical Research Results at American Society of Gene …

Scientists Discover Marker to Identify, Attack Breast Cancer Stem Cells

Cell surface protein blows potent cells cover; targeted drug works in preclinical tests

Newswise HOUSTON Breast cancer stem cells wear a cell surface protein that is part nametag and part bulls eye, identifying them as potent tumor-generating cells and flagging their vulnerability to a drug, researchers at The University of Texas MD Anderson Cancer Center report online in Journal of Clinical Investigation.

Weve discovered a single marker for breast cancer stem cells and also found that its targetable with a small molecule drug that inhibits an enzyme crucial to its synthesis, said co-senior author Michael Andreeff, M.D., Ph.D., professor in MD Andersons Departments of Leukemia and Stem Cell Transplantation and Cellular Therapy.

Andreeff and colleagues are refining the drug as a potential targeted therapy for breast cancer stem cells, which are thought to be crucial to therapy resistance, disease progression and spread to other organs.

Its been difficult to identify cancer stem cells in solid tumors, Andreeff said. And nobody has managed to target these cells very well.

The marker is the cell surface protein ganglioside GD2. The drug is triptolide, an experimental drug that Andreeff has used in preclinical leukemia research. The team found triptolide blocks expression of GD3 synthase, which is essential to GD2production.

Triptolide stymied cancer growth in cell line experiments and resulted in smaller tumors and prolonged survival in mouse experiments. Drug development for human trials probably will take several years.

Cancer stem cells are similar to normal stem cells

Research in several types of cancer has shown cancer stem cells are a small subpopulation of cancer cells that are capable of long-term self-renewal and generation of new tumors. More recent research shows they resist treatment and promote metastasis.

Cancer stem cells are similar to normal stem cells that renew specialized tissues. The breast cancer findings grew out of Andreeffs long-term research in mesenchymal stem cells, which can divide into one copy of themselves and one differentiated copy of a bone, muscle, fat or cartilage cell.

Link:
Scientists Discover Marker to Identify, Attack Breast Cancer Stem Cells

AxoGen, Inc. Announces Record First Quarter 2012 Revenues

ALACHUA, Fla.–(BUSINESS WIRE)–

AxoGen, Inc. (AXGN.OB), a leading regenerative medicine company focused on the commercialization of proprietary products and technologies for peripheral nerve reconstruction and regeneration, today announced revenues for the first quarter ended March 31, 2012 of $1.65 million, a 47% increase over 2011 first quarter revenues of $1.12 million.

This quarters record performance has been the direct result of our increase in sales and marketing activity, commented Karen Zaderej, Chief Executive Officer of AxoGen, Inc. During the first quarter we continued to expand our sales force, while continuing to get hospital approval for AxoGen products and training and developing the sales team. Our growing base of sales representatives, combined with increasing surgeon awareness of our technologies and clinical data, creates a strong environment for our continued growth.

Revenues Revenues for the period increased to a record $1.65 million, or 47%, compared to $1.12 million in 2011. The improved results were primarily due to an increase in new accounts as well as stronger sales penetration into key accounts.

Revenues increased 21% over fourth quarter revenues of $1.36 million.

Gross Profit Gross profit reached $1.21 million, a 55% increase, for first quarter 2012 up from $0.78 million reported for the same period 2011. The higher gross profit reflects lower manufacturing and labor cost and the absence of one-time manufacturing startup expenses reported during the first quarter of 2011. The gross profit margin increased to 73% compared to 70% for the same quarter last year.

Sales and Marketing Expenses As a result of the Company’s investment in additional sales and marketing resources, sales and marketing expenses during the first quarter of 2011 increased to $1.63 million, compared to $0.86 million reported during the same period last year. As of the end of the period, the Company reported 16 direct and 21 independent sales representatives and distributors.

Research and Development Expenses Research and development expenses increased to $0.30 million during the first quarter of 2012. Substantially all of the research and development expenses relate to expenditures for clinical activity.

General and Administrative Expenses General and administrative expenses increased to $1.23 million for the quarter, compared to $0.72 million reported last year. This increase was largely driven by payroll and benefit increases and expenses associated with being a public company.

Operating Loss The Company reported a net loss of $2.11 million, or $0.19 per common share, compared to a net loss of $2.3 million, or $2.21 per common share, reported during the same period in 2011.

See the article here:
AxoGen, Inc. Announces Record First Quarter 2012 Revenues

Avita Medical Initiates US FDA Study of Its ReCell® Spray-On-Skin™ for Reconstructive and Aesthetic Indications

NORTHRIDGE, Calif. & CAMBRIDGE, England–(BUSINESS WIRE)–

Avita Medical Ltd. (ASX: AVH), (OTC: AVMXF), (OTCQX: AVMXY),the regenerative medicine company, today announced that it has commenced enrolment in the US FDA-approved feasibility study for the use of ReCell Spray-On-Skin in the treatment of hypertrophic dyspigmented scars (raised and/or discoloured scars).

The initial three patients were treated by Dr Rajiv Sood, at the Richard M. Fairbanks Burn Center of Wishard Hospital, Indiana University, Indianapolis, Indiana, for scarring resulting from previous grafting due to burn injuries.

The approved FDA protocol permits the Company to treat 20 patients with scars at up to four U.S. study sites; patients will be assessed for healing and pain on a weekly basis during the initial four weeks post-treatment; at weeks 12 and 24 the treatment site will be assessed for healing and aesthetic outcomes by both the patient and an independent observer.

“Commencement of the FDA scar study is an important milestone for Avita,” said Dr William Dolphin, Avita Medicals CEO. “ReCell has shown the potential to provide significant benefits over current options in the treatment of acute and chronic wounds and for a wide range of skin defects. We are confident that this study will demonstrate the effectiveness of ReCell in the corrective treatment of scars, making ReCell directly applicable and immediately relevant to the very large aesthetic markets.

The feasibility study is primarily designed to confirm the effectiveness of ReCell for the treatment of scars in a single session in comparison to the current standard of care involving dermabrasion of the scar and often requiring multiple treatment sessions; study endpoints are time-to-healing and aesthetic outcomes. Following completion of the study, Avita will submit the feasibility data and seek FDA approval for a statistically powered, pivotal clinical trial.

The study is funded by the US Department of Defense in partnership with the OSD Manufacturing Technology Program and Rapid Fielding Directorate for the Limb Salvage and Regenerative Medicine Initiative. The contract is a Technology Investment Agreement that is focused on the transition of the capability to meet DoD needs. ReCell was selected as it has the potential to be a quantum advance over the existing ability to treat and re-grow tissue and to substantially reduce the effects and appearance of scarring and thereby profoundly assist in the treatment and rehabilitation of wounded warriors suffering from disfigurement and impeded function due to combat injuries.

An interview with Dr Sood regarding the use of ReCell in treatment of scars and acute wounds is available at http://soundmedicine.iu.edu/segment/3245/Spray-on-Skin.

ABOUT AVITA MEDICAL LTD.

Avita Medical (www.avitamedical.com) develops and distributes regenerative and tissue-engineered products for the treatment of a broad range of wounds, scars and skin defects. The companys lead product, ReCell Spray-On-SkinTM, is used in a wide variety of burns, plastic, reconstructive and cosmetic procedures. ReCell is patented, CE-marked for Europe, TGA-registered in Australia, and SFDA-cleared in China. ReCell is not available for sale in the United States; in the U.S. ReCell is an investigational device limited to investigational use.

Here is the original post:
Avita Medical Initiates US FDA Study of Its ReCell® Spray-On-Skin™ for Reconstructive and Aesthetic Indications

Regenerative medicine company begins enrollment in critical limb ischemia trial

Regenerative medicine startup Juventas Therapeutics has begun enrollment in a phase 2a trial of critical limb ischemia patients.

The Cleveland-based company, which recently secured an important investment from Takeda Pharmaceuticals, is planning to enroll 48 patients and complete enrollment early next year, CEO Rahul Aras said.

Juventas technology, called JVS-100, works by recruiting stem cells from the bone marrow to create new blood vessels. Its based on Stromal Cell-Derived Factor-1 (SDF-1), a naturally produced molecule that attempts to repair the heart immediately following a heart attack.

Critical limb ischemia (CLI) patients are enrolling at several U.S. hospitals, as well as three in India. CLI is a severe obstruction of the arteries that greatly decreases blood flow to the extremities.

Advertisement

CLI has become a very exciting clinical opportunity, Aras said. Its becoming a growing area of interest for a number of biotech and pharma companies.

Other companies pursuing CLI treatment include Aastrom Biosciences, Arteriocyte and Biomet.

Among the top advantages of Juventas CLI therapy is its simplicity and cost-effectiveness, Aras said. Patients can be injected with the companys therapeutic in an easy procedure at a physician office, and the approach doesnt require bone marrow aspiration to obtain patients own stem cells or complex cell processing as some competing therapeutics do.

Juventas also has a phase 2 trial underway to investigate its therapy with heart failure patients.

The company is expected to shortly announce a series B round of investment, which includes the funding from Takeda, that totals around $20 million or $25 million.

Continue reading here:
Regenerative medicine company begins enrollment in critical limb ischemia trial

Complete Genomics Sequences 600 Individuals for Diabetes Study

Genomic Health has appointed Richard Tompane as president of its new subsidiary InVitae, which will focus on developing next-generation-based sequencing diagnostics for genetic diseases. Tompane was previously president and CEO of Gemfire and has also served as an independent consultant.

LaserGen has appointed Mimi Healy its new CEO and member of the board of directors. She previously served as CEO of Houston-based Bacterial Barcodes, a spin-off company of BCM Technologies.

Trovagene has named Carlo Croce to serve on its scientific advisory board. Croce is director of the Human Cancer Genetics Program and the Genetics Institute at The Ohio State University, and he is John W. Wolfe Chair in Human Cancer Genetics.

Read the original post:
Complete Genomics Sequences 600 Individuals for Diabetes Study

Finnish CRO Admescope Adopts Plexpress' TRAC Platform for ADME-Tox Services

Genomic Health has appointed Richard Tompane as president of its new subsidiary InVitae, which will focus on developing next-generation-based sequencing diagnostics for genetic diseases. Tompane was previously president and CEO of Gemfire and has also served as an independent consultant.

LaserGen has appointed Mimi Healy its new CEO and member of the board of directors. She previously served as CEO of Houston-based Bacterial Barcodes, a spin-off company of BCM Technologies.

Trovagene has named Carlo Croce to serve on its scientific advisory board. Croce is director of the Human Cancer Genetics Program and the Genetics Institute at The Ohio State University, and he is John W. Wolfe Chair in Human Cancer Genetics.

Read more here:
Finnish CRO Admescope Adopts Plexpress' TRAC Platform for ADME-Tox Services

Molecular Screening Awareness Grows in Step with Adoption of Roche Melanoma Drug, Survey Finds

Genomic Health has appointed Richard Tompane as president of its new subsidiary InVitae, which will focus on developing next-generation-based sequencing diagnostics for genetic diseases. Tompane was previously president and CEO of Gemfire and has also served as an independent consultant.

LaserGen has appointed Mimi Healy its new CEO and member of the board of directors. She previously served as CEO of Houston-based Bacterial Barcodes, a spin-off company of BCM Technologies.

Trovagene has named Carlo Croce to serve on its scientific advisory board. Croce is director of the Human Cancer Genetics Program and the Genetics Institute at The Ohio State University, and he is John W. Wolfe Chair in Human Cancer Genetics.

Read the original post:
Molecular Screening Awareness Grows in Step with Adoption of Roche Melanoma Drug, Survey Finds

The Ventyx Wesley Research Institute Tissue Bank Joins the BioServe Network

BELTSVILLE, MD–(Marketwire -05/16/12)- BioServe today announced that the Ventyx Wesley Research Institute Tissue Bank, the largest state-of-the-art bio-repository of human tissue and blood in Queensland, Australia, has joined BioServe’s network of affiliated bio-repositories. As part of the BioServe Network, the Ventyx Wesley Research Institute Tissue Bank will make available its high volume of oncology tissue and blood samples to industry and academic researchers worldwide. The collaborative partnership between BioServe and the Wesley Research Institute was facilitated by Bio-Link Australia Pty. Ltd., a life sciences commercialisation company.

The Ventyx Wesley Research Institute Tissue Bank joins the growing BioServe Network that includes Fox Chase Cancer Center, University of Massachusetts Medical School, the Windber Research Institute, and Maine Medical Center. The Network, along with BioServe’s Global BioRepository, creates the largest commercial-ready specimen repository in the world with over 2 million samples in most major diseases. Such specimens hold the data driving genetic and biomarker discovery and validation for effective patient stratification, drug discovery and development of new diagnostics.

The Ventyx Wesley Research Institute Tissue Bank was founded in 2007 and is a purpose-built research facility established to provide a diverse collection of ethically obtained tissue specimens for biomedical research. The Tissue Bank operates at the Wesley Research Institute, which is located on the Wesley Hospital campus in Auchenflower, Brisbane. It collects and stores tissue samples, blood and related clinical data from consenting patients at The Wesley Hospital and makes these specimens and clinical data available to ethically approved medical researchers. The Tissue Bank adheres to the international standards set down in Good Clinical Practice and Good Laboratory Practice guidelines.

“We are pleased that the Ventyx Wesley Research Institute Tissue Bank will make its high quality tissue samples available through the BioServe Network. By tapping this unique and comprehensive sample resource, researchers can quickly obtain most any type of human biological sample in most any disease,” said Rama Modali, President of BioServe.

“Becoming part of the BioServe Network will enable us to reach a greater proportion of the scientific research community, putting our samples into the hands of researchers developing new therapies and diagnostics,” said Dr. Greg Hafner, Chief Operations Officer of the Wesley Research Institute.

About BioServe BioServe provides a comprehensive ‘biomaterial to validated data’ genomics services platform, helping researchers gain the pre-clinical data for breakthroughs in drug discovery, molecular diagnostics and pharmacogenomics. Utilizing BioServe’s genomics services platform, researchers can identify genetic markers, validate drug targets and correlate clinical data with molecular data to accelerate the development of new and safer drugs. BioServe’s services extend from nucleic acids processing, DNA synthesis, high throughput genotyping, genome wide-scans and gene expression analyses to ready-made large epidemiologically sound case-control studies of inflammatory disorders, endocrine disorders, cardiovascular disease, diabetes, hypertension, obesity and many cancers. BioServe’s Global BioRepository provides researchers with a library of 600,000 human DNA, tissue and serum samples linked to detailed clinical and demographic data from 120,000 consented and anonymized patients from four continents.

For more information please visit www.bioserve.com or call 301-470-3362.

About Wesley Research InstituteThe Wesley Research Institute is an independent, not-for-profit medical research organisation that conducts research focusing on improving patient care and quality of life. Its clinical and applied research aims to discover, test and refine new techniques for better diagnosis and treatment of illness and disease that work towards its motto of ‘making a difference today.’ Wesley Research Institute provides a range of scientific services across three main areas — Investigative Research, Clinical Trials and Tissue Banking.

For more information please visit www.wesleyresearch.org.au or email enquiries@wesleyresearch.com.au.

About Bio-Link AustraliaBio-Link Australia Pty. Ltd., with offices in Melbourne and Sydney, is a life sciences commercialisation company offering professional business development services to facilitate commercial partnerships in the biopharmaceutical and diagnostic industries. Bio-Link’s clients include leading biotechnology companies and medical research institutes located in Australia and around the world. For more information please visit www.bio-link.com.

See the rest here:
The Ventyx Wesley Research Institute Tissue Bank Joins the BioServe Network

Study Finds Head Impacts in Contact Sports May Reduce Learning in College Athletes

Newswise MINNEAPOLIS A new study suggests that head impacts experienced during contact sports such as football and hockey may worsen some college athletes ability to acquire new information. The research is published in the May 16, 2012, online issue of Neurology, the medical journal of the American Academy of Neurology.

The study involved college athletes at three Division I schools and compared 214 athletes in contact sports to 45 athletes in non-contact sports such as track, crew and Nordic skiing at the beginning and at the end of their seasons. The contact sport athletes wore special helmets that recorded the acceleration speed and other data at the time of any head impact.

The contact sport athletes experienced an average of 469 head impacts during the season. Athletes were not included in the study if they were diagnosed with a concussion during the season.

All of the athletes took tests of thinking and memory skills before and after the season. A total of 45 contact sport athletes and 55 non-contact sport athletes from one of the schools also took an additional set of tests of concentration, working memory and other skills.

The good news is that overall there were few differences in the test results between the athletes in contact sports and the athletes in non-contact sports, said study author Thomas W. McAllister, MD, of The Geisel School of Medicine at Dartmouth in Lebanon, N.H. But we did find that a higher percentage of the contact sport athletes had lower scores than would have been predicted after the season on a measure of new learning than the non-contact sport athletes.

A total of 22 percent of the contact sport athletes performed worse than expected on the test of new learning, compared to four percent of the non-contact sport athletes.

McAllister noted that the study did not find differences in test results between the two groups of athletes at the beginning of the season, suggesting that the cumulative head impacts that contact athletes had incurred over many previous seasons did not result in reduced thinking and memory skills in the overall group.

These results are somewhat reassuring, given the recent heightened concern about the potential negative effects of these sports, he said. Nevertheless, the findings do suggest that repetitive head impacts may have a negative effect on some athletes.

McAllister said its possible that some people may be genetically more sensitive to head impacts.

The study was supported by the National Institutes of Health and the National Operating Committee on Standards for Athletic Equipment.

Read the original post:
Study Finds Head Impacts in Contact Sports May Reduce Learning in College Athletes

United Kingdom Neurology Devices Market Outlook to 2018 – Interventional Neurology, Neurological Diagnostic Equipment …

NEW YORK, May 15, 2012 /PRNewswire/ — Reportlinker.com announces that a new market research report is available in its catalogue:

http://www.reportlinker.com/p0862102/United-Kingdom-Neurology-Devices-Market-Outlook-to-2018—Interventional-Neurology-Neurological-Diagnostic-Equipment-Neurostimulation-Devices-and-Others.html#utm_source=prnewswire&utm_medium=pr&utm_campaign=General_Medicine_and_Specialty_Medicine

United Kingdom Neurology Devices Market Outlook to 2018 – Interventional Neurology, Neurological Diagnostic Equipment, Neurostimulation Devices and Others

This report is built using data and information sourced from proprietary databases, primary and secondary research and in-house analysis by GlobalData’s team of industry experts.

Scope

– Market size and company share data for Neurology Devices market categories CSF Management, Interventional Neurology, Neurological Diagnostic Equipment, Neurostimulation Devices, Neurosurgical Products and Radiosurgery.- Annualized market revenues (USD million), volume (units) and average price (USD) data for each of the segments and sub-segments within six market categories. Data from 2004 to 2011, forecast forward for 7 years to 2018. – 2011 company shares and distribution shares data for each of the six market categories.- Global corporate-level profiles of key companies operating within the United Kingdom Neurology Devicesmarket. – Key players covered include Medtronic, Inc., St. Jude Medical, Inc., Accuray Incorporated, DePuy, Inc., Stryker Corporation, B. Braun Melsungen AG and others.

Reasons to buy

– Develop business strategies by identifying the key market categories and segments poised for strong growth.- Develop market-entry and market expansion strategies.- Design competition strategies by identifying who-stands-where in the United Kingdom Neurology Devices competitive landscape.- Develop capital investment strategies by identifying the key market segments expected to register strong growth in the near future.- What are the key distribution channels and what’s the most preferred mode of product distribution Identify, understand and capitalize.1 Table of Contents1 Table of Contents 21.1 List of Tables 81.2 List of Figures 102 Introduction 132.1 What is This Report About? 133 Neurology Devices In United Kingdom 143.1 Neurology Devices, Market Segmentation 143.2 Neurology Devices, United Kingdom, Overall Revenue ($m), USD Constant, 2004-2018 153.3 Neurology Devices Market, United Kingdom, Revenue Mix ($m), 2011 173.4 Neurology Devices Market, United Kingdom, Category Contribution (%), 2011 183.5 Neurology Devices, United Kingdom, Company Share (2010-2011) 244 CSF Management In United Kingdom 264.1 CSF Management, Market Segmentation 264.2 CSF Management Market, United Kingdom, Revenue Mix ($m), 2011 274.3 CSF Management Market, United Kingdom, Segment Contribution (%), 2011 284.4 CSF Management Overall Revenue, (2004-2018) 294.5 CSF Management Overall Volume (2004-2018) 334.6 CSF Management Average Price (2004-2018) 354.7 CSF Management Distribution Share (2010-2011) 354.8 CSF Management, United Kingdom, Company Share (2010-2011) 365 Interventional Neurology In United Kingdom 385.1 Interventional Neurology, Market.Segmentation 385.2 Interventional Neurology Market, United Kingdom, Revenue Mix ($m), 2011 395.3 Interventional Neurology Market, United Kingdom, Segment Contribution (%), 2011 405.4 Interventional Neurology Overall Revenue, (2004-2018) 415.4.1 Embolic Systems Revenue (2004-2018) 455.4.2 Navigational Systems Revenue (2004-2018) 495.5 Interventional Neurology Overall Volume (2004-2018) 535.5.1 Embolic Systems Volume (2004-2018) 575.5.2 Navigational Systems Volume (2004-2018) 595.6 Interventional Neurology Average Price (2004-2018) 615.7 Interventional Neurology Distribution Share (2010-2011) 625.8 Interventional Neurology, United Kingdom, Company Share (2010-2011) 636 Neurological Diagnostic Equipment In United Kingdom 656.1 Neurological Diagnostic Equipment, Market.Segmentation 656.2 Neurological Diagnostic Equipment Market, United Kingdom, Revenue Mix ($m), 2011 666.3 Neurological Diagnostic Equipment Market, United Kingdom, Segment Contribution (%), 2011 676.4 Neurological Diagnostic Equipment Overall Revenue, (2004-2018) 686.5 Neurological Diagnostic Equipment Overall Volume (2004-2018) 726.6 Neurological Diagnostic Equipment Average Price (2004-2018) 766.7 Neurological Diagnostic Equipment Distribution Share (2010-2011) 776.8 Neurological Diagnostic Equipment, United Kingdom, Company Share (2010-2011) 787 Neurostimulation Devices In United Kingdom 807.1 Neurostimulation Devices, Market Segmentation 807.2 Neurostimulation Devices Market, United Kingdom, Revenue Mix ($m), 2011 817.3 Neurostimulation Devices Market, United Kingdom, Segment Contribution (%), 2011 827.4 Neurostimulation Devices Overall Revenue, (2004-2018) 837.5 Neurostimulation Devices Overall Volume (2004-2018) 877.6 Neurostimulation Devices Average Price (2004-2018) 917.7 Neurostimulation Devices Distribution Share (2010-2011) 927.8 Neurostimulation Devices, United Kingdom, Company Share (2010-2011) 938 Neurosurgical Products In United Kingdom 948.1 Neurosurgical Products, Market Segmentation 948.2 Neurosurgical Products Market, United Kingdom, Revenue Mix ($m), 2011 958.3 Neurosurgical Products Market, United Kingdom, Segment Contribution (%), 2011 968.4 Neurosurgical Products Overall Revenue, (2004-2018) 978.5 Neurosurgical Products Overall Volume (2004-2018) 1018.6 Neurosurgical Products Average Price (2004-2018) 1038.7 Neurosurgical Products Distribution Share (2010-2011) 1038.8 Neurosurgical Products, United Kingdom, Company Share (2010-2011) 1049 Radiosurgery In United Kingdom 1059.1 Radiosurgery, Market Segmentation 1059.2 Radiosurgery Market, United Kingdom, Revenue Mix ($m), 2011 1069.3 Radiosurgery Market, United Kingdom, Segment Contribution (%), 2011 1079.4 Radiosurgery Overall Revenue, (2004-2011) 1089.5 Radiosurgery Overall Volume (2004-2011) 1109.6 Radiosurgery Average Price (2004-2011) 1119.7 Radiosurgery Distribution Share (2010-2011) 1119.8 Radiosurgery, United Kingdom, Company Share (2010-2011) 11210 Overview of Key Companies in United Kingdom Neurology Devices Market 11310.1 Medtronic, Inc. 11310.1.1 Company Overview 11310.1.2 Share in the United Kingdom Neurology Devices Market 11310.2 St. Jude Medical, Inc. 11410.2.1 Company Overview 11410.2.2 Share in the United Kingdom Neurology Devices Market 11410.3 Accuray Incorporated 11510.3.1 Company Overview 11510.3.2 Share in the United Kingdom Neurology Devices Market 11510.4 DePuy, Inc. 11610.4.1 Company Overview 11610.4.2 Share in the United Kingdom Neurology Devices Market 11610.5 Stryker Corporation 11710.5.1 Company Overview 11710.5.2 Share in the United Kingdom Neurology Devices Market 11710.6 B. Braun Melsungen AG 11810.6.1 Company Overview 11810.6.2 Share in the United Kingdom Neurology Devices Market 11810.7 Boston Scientific Corporation 11910.7.1 Company Overview 11910.8 Cyberonics, Inc. 11910.8.1 Company Overview 11910.9 Terumo Corporation 12010.9.1 Company Overview 12010.10 Integra LifeSciences Holdings Corporation 12010.10.1 Company Overview 12010.11 Cadwell Laboratories, Inc. 12010.11.1 Company Overview 12010.12 Natus Medical Incorporated 12110.12.1 Company Overview 12110.13 Micromed S.p.A 12110.13.1 Company Overview 12110.14 Christoph Miethke GmbH & Co. KG 12110.14.1 Company Overview 12110.15 CareFusion Corporation 12210.15.1 Company Overview 12210.16 Nihon Kohden Corporation 12210.16.1 Company Overview 12210.17 KARL STORZ GmbH & Co. KG 12310.17.1 Company Overview 12310.18 Sophysa S.A. 12310.18.1 Company Overview 12310.19 Covidien plc 12310.19.1 Company Overview 12310.20 Elekta AB 12410.20.1 Company Overview 12411 Neurology Devices Market Pipeline Products 12512 Financial Deals Landscape 13112.1 Partnerships 13112.1.1 GE Healthcare Enters Into A Distribution Agreement With KC BioMedix 13113 Recent Developments 13213.1 Government and Public Interest 13213.1.1 Apr 23, 2012: New Technique May Help Severely Damaged Nerves Regrow And Restore Function: University of Sheffield 13213.1.2 Jan 10, 2012: Fusion Plasma Research Helps Neurologists To Hear Above The Noise 13314 Appendix 13514.1 Definitions of Markets Covered in the Report 13614.1.1 Neurology Devices 13614.2 Research Methodology 14014.3 Secondary Research 14014.4 Primary Research 14114.5 Models 14114.6 Forecasts 14214.7 Expert Panels 14214.8 GlobalData Consulting 14214.9 Currency Conversion 14314.10 Contact Us 14314.11 Disclaimer 143

List of Tables

Table 1: Neurology Devices, United Kingdom, Overall Revenue ($m), USD Constant, 2004-2018 15Table 2: Neurology Devices Market, United Kingdom, Category Contribution (%), 2011 17Table 3: Neurology Devices, United Kingdom, Cross-Category Analysis, 2004-2018 18Table 4: Neurology Devices, United Kingdom, Overall Revenue ($m), USD Constant, Historic, 2004-2011 20Table 5: Neurology Devices, United Kingdom, Overall Revenue ($m), USD Constant, Forecast, 2011-2018 22Table 6: Neurology Devices, United Kingdom, Company Share by Revenue ($m), USD Constant, 2010-2011 24Table 7: CSF Management Market, United Kingdom, Segment Contribution (%), 2011 27Table 8: CSF Management, United Kingdom, Revenue ($m) USD Constant, by Segment, Historic, 2004-2011 29Table 9: CSF Management, United Kingdom, Revenue ($m) USD Constant, by Segment, Forecast, 2011-2018 31Table 10: CSF Management, United Kingdom, Volume (Units) by Segment, Historic, 2004-2011 32Table 11: CSF Management, United Kingdom, Volume (Units) by Segment, Forecast, 2011-2018 33Table 12: CSF Management, United Kingdom, Average Price ($), Historic, 2004-2011 34Table 13: CSF Management, United Kingdom, Average Price ($), Forecast, 2011-2018 34Table 14: CSF Management, United Kingdom, Distribution Share by Revenue ($m), USD Constant, 2010-2011 34Table 15: CSF Management, United Kingdom, Company Share by Revenue ($m), USD Constant, 2010-2011 36Table 16: Interventional Neurology Market, United Kingdom, Segment Contribution (%), 2011 39Table 17: Interventional Neurology, United Kingdom, Revenue ($m*) USD Constant, by Segment, Historic, 2004-2011 41Table 18: Interventional Neurology, United Kingdom, Revenue ($m*) USD Constant, by Segment, Forecast, 2011-2018 43Table 19: Embolic Systems, United Kingdom, Revenue ($m) USD Constant, by Sub-Segment, Historic, 2004-2011 45Table 20: Embolic Systems, United Kingdom, Revenue ($m) USD Constant, by Sub-Segment, Forecast, 2011-2018 47Table 21: Navigational Systems, United Kingdom, Revenue ($m) USD Constant, by Sub-Segment, Historic, 2004-2011 49Table 22: Navigational Systems, United Kingdom, Revenue ($m) USD Constant, by Sub-Segment, Forecast, 2011-2018 51Table 23: Interventional Neurology, United Kingdom, Volume (Units) by Segment, Historic, 2004-2011 53Table 24: Interventional Neurology, United Kingdom, Volume (Units) by Segment, Forecast, 2011-2018 55Table 25: Embolic Systems, United Kingdom, Volume (Units) by Sub-Segment, Historic, 2004-2011 56Table 26: Embolic Systems, United Kingdom, Volume (Units) by Sub-Segment, Forecast, 2011-2018 57Table 27: Navigational Systems, United Kingdom, Volume (Units) by Sub-Segment, Historic, 2004-2011 58Table 28: Navigational Systems, United Kingdom, Volume (Units) by Sub-Segment, Forecast, 2011-2018 59Table 29: Interventional Neurology, United Kingdom, Average Price ($), Historic, 2004-2011 60Table 30: Interventional Neurology, United Kingdom, Average Price ($), Forecast, 2011-2018 60Table 31: Interventional Neurology, United Kingdom, Distribution Share by Revenue ($m), USD Constant, 2010-2011 61Table 32: Interventional Neurology, United Kingdom, Company Share by Revenue ($m), USD Constant, 2010-2011 63Table 33: Neurological Diagnostic Equipment Market, United Kingdom, Segment Contribution (%), 2011 66Table 34: Neurological Diagnostic Equipment, United Kingdom, Revenue ($m) USD Constant, by Segment, Historic, 2004-2011 68Table 35: Neurological Diagnostic Equipment, United Kingdom, Revenue ($m) USD Constant, by Segment, Forecast, 2011-2018 70Table 36: Neurological Diagnostic Equipment, United Kingdom, Volume (Units) by Segment, Historic, 2004-2011 72Table 37: Neurological Diagnostic Equipment, United Kingdom, Volume (Units) by Segment, Forecast, 2011-2018 74Table 38: Neurological Diagnostic Equipment, United Kingdom, Average Price ($), Historic, 2004-2011 75Table 39: Neurological Diagnostic Equipment, United Kingdom, Average Price ($), Forecast, 2011-2018 75Table 40: Neurological Diagnostic Equipment, United Kingdom, Distribution Share by Revenue ($m), USD Constant, 2010-2011 76Table 41: Neurological Diagnostic Equipment, United Kingdom, Company Share by Revenue ($m), USD Constant, 2010-2011 78Table 42: Neurostimulation Devices Market, United Kingdom, Segment Contribution (%), 2011 81Table 43: Neurostimulation Devices, United Kingdom, Revenue ($m) USD Constant, by Segment, Historic, 2004-2011 83Table 44: Neurostimulation Devices, United Kingdom, Revenue ($m) USD Constant, by Segment, Forecast, 2011-2018 85Table 45: Neurostimulation Devices, United Kingdom, Volume (Units) by Segment, Historic, 2004-2011 87Table 46: Neurostimulation Devices, United Kingdom, Volume (Units) by Segment, Forecast, 2011-2018 89Table 47: Neurostimulation Devices, United Kingdom, Average Price ($), Historic, 2004-2011 90Table 48: Neurostimulation Devices, United Kingdom, Average Price ($), Forecast, 2011-2018 90Table 49: Neurostimulation Devices, United Kingdom, Distribution Share by Revenue ($m), USD Constant, 2010-2011 91Table 50: Neurostimulation Devices, United Kingdom, Company Share by Revenue ($m), USD Constant, 2010-2011 92Table 51: Neurosurgical Products Market, United Kingdom, Segment Contribution (%), 2011 95Table 52: Neurosurgical Products, United Kingdom, Revenue ($m) USD Constant, by Segment, Historic, 2004-2011 97Table 53: Neurosurgical Products, United Kingdom, Revenue ($m) USD Constant, by Segment, Forecast, 2011-2018 99Table 54: Neurosurgical Products, United Kingdom, Volume (Units) by Segment, Historic, 2004-2011 100Table 55: Neurosurgical Products, United Kingdom, Volume (Units) by Segment, Forecast, 2011-2018 101Table 56: Neurosurgical Products, United Kingdom, Average Price ($), Historic, 2004-2011 102Table 57: Neurosurgical Products, United Kingdom, Average Price ($), Forecast, 2011-2018 102Table 58: Neurosurgical Products, United Kingdom, Distribution Share by Revenue ($m), USD Constant, 2010-2011 102Table 59: Neurosurgical Products, United Kingdom, Company Share by Revenue ($m), USD Constant, 2010-2011 103Table 60: Radiosurgery Market, United Kingdom, Segment Contribution (%), 2011 106Table 61: Radiosurgery, United Kingdom, Revenue ($m) USD Constant, by Segment, Historic, 2004-2011 108Table 62: Radiosurgery, United Kingdom, Volume (Units) by Segment, Historic, 2004-2011 109Table 63: Radiosurgery, United Kingdom, Average Price ($), Historic, 2004-2011 110Table 64: Radiosurgery, United Kingdom, Distribution Share by Revenue ($m), USD Constant, 2010-2011 110Table 65: Radiosurgery, United Kingdom, Company Share by Revenue ($m), USD Constant, 2010-2011 111Table 66: Neurology Devices Market Pipeline Products 124Table 67: GE Healthcare Enters Into A Distribution Agreement With KC BioMedix 130

Read this article:
United Kingdom Neurology Devices Market Outlook to 2018 – Interventional Neurology, Neurological Diagnostic Equipment …

China Neurology Devices Market Outlook to 2018 – Interventional Neurology, Neurological Diagnostic Equipment …

NEW YORK, May 15, 2012 /PRNewswire/ — Reportlinker.com announces that a new market research report is available in its catalogue: China Neurology Devices Market Outlook to 2018 – Interventional Neurology, Neurological Diagnostic Equipment, Neurostimulation Devices and Othershttp://www.reportlinker.com/p0862105/China-Neurology-Devices-Market-Outlook-to-2018—Interventional-Neurology-Neurological-Diagnostic-Equipment-Neurostimulation-Devices-and-Others.html#utm_source=prnewswire&utm_medium=pr&utm_campaign=General_Medicine_and_Specialty_Medicine

China Neurology Devices Market Outlook to 2018 – Interventional Neurology, Neurological Diagnostic Equipment, Neurostimulation Devices and Others

Summary

GlobalData’s new report, “China Neurology Devices Market Outlook to 2018 – Interventional Neurology, Neurological Diagnostic Equipment, Neurostimulation Devices and Others” provides key market data on the China Neurology Devices market. The report provides value (USD million), volume (units) and average price (USD) data for each segment and sub-segment within six market categories CSF Management, Interventional Neurology, Neurological Diagnostic Equipment, Neurostimulation Devices, Neurosurgical Products and Radiosurgery. The report also provides company shares and distribution shares data for each of the aforementioned market categories. The report is supplemented with global corporate-level profiles of the key market participants with information on company financials and pipeline products, wherever available.

This report is built using data and information sourced from proprietary databases, primary and secondary research and in-house analysis by GlobalData’s team of industry experts.

Scope

– Market size and company share data for Neurology Devices market categories CSF Management, Interventional Neurology, Neurological Diagnostic Equipment, Neurostimulation Devices, Neurosurgical Products and Radiosurgery. – Annualized market revenues (USD million), volume (units) and average price (USD) data for each of the segments and sub-segments within six market categories. Data from 2004 to 2011, forecast forward for 7 years to 2018. – 2011 company shares and distribution shares data for each of the six market categories. – Global corporate-level profiles of key companies operating within the China Neurology Devices market. – Key players covered include Medtronic, Inc., Accuray Incorporated, DePuy, Inc., B. Braun Melsungen AG, CareFusion Corporation, St. Jude Medical, Inc. and others.

Reasons to buy

– Develop business strategies by identifying the key market categories and segments poised for strong growth. – Develop market-entry and market expansion strategies. – Design competition strategies by identifying who-stands-where in the China Neurology Devices competitive landscape. – Develop capital investment strategies by identifying the key market segments expected to register strong growth in the near future. – What are the key distribution channels and what’s the most preferred mode of product distribution Identify, understand and capitalize.

1 Table of Contents

The rest is here:
China Neurology Devices Market Outlook to 2018 – Interventional Neurology, Neurological Diagnostic Equipment …

India Neurology Devices Market Outlook to 2018 – Interventional Neurology, Neurological Diagnostic Equipment …

NEW YORK, May 15, 2012 /PRNewswire/ — Reportlinker.com announces that a new market research report is available in its catalogue:

http://www.reportlinker.com/p0862104/India-Neurology-Devices-Market-Outlook-to-2018—Interventional-Neurology-Neurological-Diagnostic-Equipment-Neurostimulation-Devices-and-Others.html#utm_source=prnewswire&utm_medium=pr&utm_campaign=General_Medicine_and_Specialty_Medicine

India Neurology Devices Market Outlook to 2018 – Interventional Neurology, Neurological Diagnostic Equipment, Neurostimulation Devices and Others

This report is built using data and information sourced from proprietary databases, primary and secondary research and in-house analysis by GlobalData’s team of industry experts.

Scope

– Market size and company share data for Neurology Devices market categories CSF Management, Interventional Neurology, Neurological Diagnostic Equipment, Neurostimulation Devices, Neurosurgical Products and Radiosurgery.- Annualized market revenues (USD million), volume (units) and average price (USD) data for each of the segments and sub-segments within six market categories. Data from 2004 to 2011, forecast forward for 7 years to 2018. – 2011 company shares and distribution shares data for each of the six market categories.- Global corporate-level profiles of key companies operating within the India Neurology Devices market. – Key players covered include Terumo Corporation, Medtronic, Inc., DePuy, Inc., CareFusion Corporation, Stryker Corporation, Covidien plc and others.

Reasons to buy

– Develop business strategies by identifying the key market categories and segments poised for strong growth.- Develop market-entry and market expansion strategies.- Design competition strategies by identifying who-stands-where in the India Neurology Devices competitive landscape.- Develop capital investment strategies by identifying the key market segments expected to register strong growth in the near future.- What are the key distribution channels and what’s the most preferred mode of product distribution Identify, understand and capitalize.1 Table of Contents1 Table of Contents 21.1 List of Tables 71.2 List of Figures 92 Introduction 112.1 What Is This Report About? 113 Neurology Devices In India 123.1 Neurology Devices, Market Segmentation 123.2 Neurology Devices, India, Overall Revenue ($m), USD Constant, 2004-2018 133.3 Neurology Devices Market, India, Revenue Mix ($m), 2011 153.4 Neurology Devices Market, India, Category Contribution (%), 2011 163.5 Neurology Devices, India, Company Share (2010-2011) 234 CSF Management In India 254.1 CSF Management, Market Segmentation 254.2 CSF Management Market, India, Revenue Mix ($m), 2011 264.3 CSF Management Market, India, Segment Contribution (%), 2011 274.4 CSF Management Overall Revenue, (2004-2018) 284.5 CSF Management Overall Volume (2004-2018) 324.6 CSF Management Average Price (2004-2018) 344.7 CSF Management Distribution Share (2010-2011) 354.8 CSF Management, India, Company Share (2010-2011) 365 Interventional Neurology In India 385.1 Interventional Neurology, Market.Segmentation 385.2 Interventional Neurology Market, India, Revenue Mix ($m), 2011 395.3 Interventional Neurology Market, India, Segment Contribution (%), 2011 405.4 Interventional Neurology Overall Revenue, (2004-2018) 415.4.1 Embolic Systems, Revenue (2004-2018) 455.4.2 Navigational Systems, Revenue (2004-2018) 495.5 Interventional Neurology Overall Volume (2004-2018) 535.5.1 Embolic Systems, Volume (2004-2018) 575.5.2 Navigational Systems, Volume (2004-2018) 595.6 Interventional Neurology Average Price (2004-2018) 615.7 Interventional Neurology Distribution Share (2010-2011) 625.8 Interventional Neurology, India, Company Share (2010-2011) 636 Neurological Diagnostic Equipment In India 656.1 Neurological Diagnostic Equipment, Market.Segmentation 656.2 Neurological Diagnostic Equipment Market, India, Revenue Mix ($m), 2011 666.3 Neurological Diagnostic Equipment Market, India, Segment Contribution (%), 2011 676.4 Neurological Diagnostic Equipment Overall Revenue, (2004-2018) 686.5 Neurological Diagnostic Equipment Overall Volume (2004-2018) 726.6 Neurological Diagnostic Equipment Average Price (2004-2018) 766.7 Neurological Diagnostic Equipment Distribution Share (2010-2011) 776.8 Neurological Diagnostic Equipment, India, Company Share (2010-2011) 787 Neurostimulation Devices In India 807.1 Neurostimulation Devices, Market Segmentation 807.2 Neurostimulation Devices Market, India, Revenue Mix ($m), 2011 817.3 Neurostimulation Devices Market, India, Segment Contribution (%), 2011 827.4 Neurostimulation Devices Overall Revenue, (2004-2018) 837.5 Neurostimulation Devices Overall Volume (2004-2018) 877.6 Neurostimulation Devices Average Price (2004-2018) 917.7 Neurostimulation Devices Distribution Share (2010-2011) 927.8 Neurostimulation Devices, India, Company Share (2010-2011) 938 Neurosurgical Products In India 958.1 Neurosurgical Products, Market Segmentation 958.2 Neurosurgical Products Market, India, Revenue Mix ($m), 2011 968.3 Neurosurgical Products Market, India, Segment Contribution (%), 2011 978.4 Neurosurgical Products Overall Revenue, (2004-2018) 988.5 Neurosurgical Products Overall Volume (2004-2018) 1028.6 Neurosurgical Products Average Price (2004-2018) 1048.7 Neurosurgical Products Distribution Share (2010-2011) 1058.8 Neurosurgical Products, India, Company Share (2010-2011) 1069 Radiosurgery In India 1089.1 Radiosurgery, Market Segmentation 1089.2 Radiosurgery Overall Revenue, (2004-2011) 1099.3 Radiosurgery Overall Volume (2004-2011) 1109.4 Radiosurgery Average Price (2004-2011) 1119.5 Radiosurgery Distribution Share (2010-2011) 1119.6 Radiosurgery, India, Company Share (2010-2011) 11110 Overview of Key Companies in India Neurology Devices Market 11210.1 Terumo Corporation 11210.1.1 Company Overview 11210.1.2 Share in the India Neurology Devices Market 11210.2 Medtronic, Inc. 11310.2.1 Company Overview 11310.2.2 Share in the India Neurology Devices Market 11310.3 DePuy, Inc. 11410.3.1 Company Overview 11410.3.2 Share in the India Neurology Devices Market 11410.4 CareFusion Corporation 11510.4.1 Company Overview 11510.4.2 Share in the India Neurology Devices Market 11510.5 Stryker Corporation 11610.5.1 Company Overview 11610.5.2 Share in the India Neurology Devices Market 11610.6 Covidien plc 11710.6.1 Company Overview 11710.6.2 Share in the India Neurology Devices Market 11710.7 Elekta AB 11810.7.1 Company Overview 11810.8 B. Braun Melsungen AG 11810.8.1 Company Overview 11810.9 Sophysa S.A. 11910.9.1 Company Overview 11910.10 Integra LifeSciences Holdings Corporation 11910.10.1 Company Overview 11910.11 Natus Medical Incorporated 12010.11.1 Company Overview 12010.12 St. Jude Medical, Inc. 12010.12.1 Company Overview 12010.13 Nihon Kohden Corporation 12110.13.1 Company Overview 12110.14 Christoph Miethke GmbH & Co. KG 12110.14.1 Company Overview 12110.15 KARL STORZ GmbH & Co. KG 12110.15.1 Company Overview 12110.16 Cadwell Laboratories, Inc. 12210.16.1 Company Overview 12210.17 Boston Scientific Corporation 12210.17.1 Company Overview 12210.18 Cyberonics, Inc. 12210.18.1 Company Overview 12210.19 G. Surgiwear Limited 12310.19.1 Company Overview 12311 Neurology Devices Market Pipeline Products 12412 Appendix 12912.1 Definitions of Markets Covered in the Report 13012.1.1 Neurology Devices 13012.2 Research Methodology 13412.3 Secondary Research 13412.4 Primary Research 13412.5 Models 13512.6 Forecasts 13512.7 Expert Panels 13612.8 GlobalData Consulting 13612.9 Currency Conversion 13612.10 Contact Us 13612.11 Disclaimer 136

List of Tables

Table 1: Neurology Devices, India, Overall Revenue ($m), USD Constant, 2004-2018 14Table 2: Neurology Devices Market, India, Category Contribution (%), 2011 16Table 3: Neurology Devices, India, Cross-Category Analysis, 2004-2018 18Table 4: Neurology Devices, India, Overall Revenue ($m), USD Constant, Historic, 2004-2011 20Table 5: Neurology Devices, India, Overall Revenue ($m), USD Constant, Forecast, 2011-2018 22Table 6: Neurology Devices, India, Company Share by Revenue ($m), USD Constant, 2010-2011 24Table 7: CSF Management Market, India, Segment Contribution (%), 2011 27Table 8: CSF Management, India, Revenue ($m) USD Constant, by Segment, Historic, 2004-2011 29Table 9: CSF Management, India, Revenue ($m) USD Constant, by Segment, Forecast, 2011-2018 31Table 10: CSF Management, India, Volume (Units) by Segment, Historic, 2004-2011 32Table 11: CSF Management, India, Volume (Units) by Segment, Forecast, 2011-2018 33Table 12: CSF Management, India, Average Price ($), Historic, 2004-2011 34Table 13: CSF Management, India, Average Price ($), Forecast, 2011-2018 34Table 14: CSF Management, India, Distribution Share by Revenue ($m), USD Constant, 2010-2011 35Table 15: CSF Management, India, Company Share by Revenue ($m), USD Constant, 2010-2011 37Table 16: Interventional Neurology Market, India, Segment Contribution (%), 2011 40Table 17: Interventional Neurology, India, Revenue ($m) USD Constant, by Segment, Historic, 2004-2011 42Table 18: Interventional Neurology, India, Revenue ($m) USD Constant, by Segment, Forecast, 2011-2018 44Table 19: Embolic Systems, India, Revenue ($m) USD Constant, by Sub-Segment, Historic, 2004-2011 46Table 20: Embolic Systems, India, Revenue ($m) USD Constant, by Sub-Segment, Forecast, 2011-2018 48Table 21: Navigational Systems, India, Revenue ($m) USD Constant, by Sub-Segment, Historic, 2004-2011 50Table 22: Navigational Systems, India, Revenue ($m) USD Constant, by Sub-Segment, Forecast, 2011-2018 52Table 23: Interventional Neurology, India, Volume (Units) by Segment, Historic, 2004-2011 54Table 24: Interventional Neurology, India, Volume (Units) by Segment, Forecast, 2011-2018 56Table 25: Embolic Systems, India, Volume (Units) by Sub-Segment, Historic, 2004-2011 57Table 26: Embolic Systems, India, Volume (Units) by Sub-Segment, Forecast, 2011-2018 58Table 27: Navigational Systems, India, Volume (Units) by Sub-Segment, Historic, 2004-2011 59Table 28: Navigational Systems, India, Volume (Units) by Sub-Segment, Forecast, 2011-2018 60Table 29: Interventional Neurology, India, Average Price ($), Historic, 2004-2011 61Table 30: Interventional Neurology, India, Average Price ($), Forecast, 2011-2018 61Table 31: Interventional Neurology, India, Distribution Share by Revenue ($m), USD Constant, 2010-2011 62Table 32: Interventional Neurology, India, Company Share by Revenue ($m), USD Constant, 2010-2011 64Table 33: Neurological Diagnostic Equipment Market, India, Segment Contribution (%), 2011 67Table 34: Neurological Diagnostic Equipment, India, Revenue ($m) USD Constant, by Segment, Historic, 2004-2011 69Table 35: Neurological Diagnostic Equipment, India, Revenue ($m) USD Constant, by Segment, Forecast, 2011-2018 71Table 36: Neurological Diagnostic Equipment, India, Volume (Units) by Segment, Historic, 2004-2011 73Table 37: Neurological Diagnostic Equipment, India, Volume (Units) by Segment, Forecast, 2011-2018 75Table 38: Neurological Diagnostic Equipment, India, Average Price ($), Historic, 2004-2011 76Table 39: Neurological Diagnostic Equipment, India, Average Price ($), Forecast, 2011-2018 76Table 40: Neurological Diagnostic Equipment, India, Distribution Share by Revenue ($m), USD Constant, 2010-2011 77Table 41: Neurological Diagnostic Equipment, India, Company Share by Revenue ($m), USD Constant, 2010-2011 79Table 42: Neurostimulation Devices Market, India, Segment Contribution (%), 2011 82Table 43: Neurostimulation Devices, India, Revenue ($m) USD Constant, by Segment, Historic, 2004-2011 84Table 44: Neurostimulation Devices, India, Revenue ($m) USD Constant, by Segment, Forecast, 2011-2018 86Table 45: Neurostimulation Devices, India, Volume (Units) by Segment, Historic, 2004-2011 88Table 46: Neurostimulation Devices, India, Volume (Units) by Segment, Forecast, 2011-2018 90Table 47: Neurostimulation Devices, India, Average Price ($), Historic, 2004-2011 91Table 48: Neurostimulation Devices, India, Average Price ($), Forecast, 2011-2018 91Table 49: Neurostimulation Devices, India, Distribution Share by Revenue ($m), USD Constant, 2010-2011 92Table 50: Neurostimulation Devices, India, Company Share by Revenue ($m), USD Constant, 2010-2011 94Table 51: Neurosurgical Products Market, India, Segment Contribution (%), 2011 97Table 52: Neurosurgical Products, India, Revenue ($m) USD Constant, by Segment, Historic, 2004-2011 99Table 53: Neurosurgical Products, India, Revenue ($m) USD Constant, by Segment, Forecast, 2011-2018 101Table 54: Neurosurgical Products, India, Volume (Units) by Segment, Historic, 2004-2011 102Table 55: Neurosurgical Products, India, Volume (Units) by Segment, Forecast, 2011-2018 103Table 56: Neurosurgical Products, India, Average Price ($), Historic, 2004-2011 104Table 57: Neurosurgical Products, India, Average Price ($), Forecast, 2011-2018 104Table 58: Neurosurgical Products, India, Distribution Share by Revenue ($m), USD Constant, 2010-2011 105Table 59: Neurosurgical Products, India, Company Share by Revenue ($m), USD Constant, 2010-2011 107Table 60: Radiosurgery, India, Revenue ($m) USD Constant, by Segment, Historic, 2004-2011 109Table 61: Radiosurgery, India, Volume (Units) by Segment, Historic, 2004-2011 110Table 62: Radiosurgery, India, Average Price ($), Historic, 2004-2011 111Table 63: Radiosurgery, India, Distribution Share by Revenue ($m), USD Constant, 2010-2011 111Table 64: Radiosurgery, India, Company Share by Revenue ($m), USD Constant, 2010-2011 111Table 65: Neurology Devices Market Pipeline Products 124

Excerpt from:
India Neurology Devices Market Outlook to 2018 – Interventional Neurology, Neurological Diagnostic Equipment …

United States Neurology Devices Market Outlook to 2018 – Interventional Neurology, Neurological Diagnostic Equipment …

NEW YORK, May 15, 2012 /PRNewswire/ — Reportlinker.com announces that a new market research report is available in its catalogue:

United States Neurology Devices Market Outlook to 2018 – Interventional Neurology, Neurological Diagnostic Equipment, Neurostimulation Devices and Others

http://www.reportlinker.com/p0862101/United-States-Neurology-Devices-Market-Outlook-to-2018—Interventional-Neurology-Neurological-Diagnostic-Equipment-Neurostimulation-Devices-and-Others.html#utm_source=prnewswire&utm_medium=pr&utm_campaign=General_Medicine_and_Specialty_Medicine

United States Neurology Devices Market Outlook to 2018 – Interventional Neurology, Neurological Diagnostic Equipment, Neurostimulation Devices and Others

Summary

GlobalData’s new report, “United States Neurology Devices Market Outlook to 2018 – Interventional Neurology, Neurological Diagnostic Equipment, Neurostimulation Devices and Others” provides key market data on the United States Neurology Devices market. The report provides value (USD million), volume (units) and average price (USD) data for each segment and sub-segment within six market categories CSF Management, Interventional Neurology, Neurological Diagnostic Equipment, Neurostimulation Devices, Neurosurgical Products and Radiosurgery. The report also provides company shares and distribution shares data for each of the aforementioned market categories. The report is supplemented with global corporate-level profiles of the key market participants with information on company financials and pipeline products, wherever available.

This report is built using data and information sourced from proprietary databases, primary and secondary research and in-house analysis by GlobalData’s team of industry experts.

– Annualized market revenues (USD million), volume (units) and average price (USD) data for each of the segments and sub-segments within six market categories. Data from 2004 to 2011, forecast forward for 7 years to 2018.

– 2011 company shares and distribution shares data for each of the six market categories.

– Global corporate-level profiles of key companies operating within the United States Neurology Devicesmarket.

The rest is here:
United States Neurology Devices Market Outlook to 2018 – Interventional Neurology, Neurological Diagnostic Equipment …

Industrial Nanotech, Inc. Announces Expansion to India with Corporate Sales Office

NAPLES, Fla.–(BUSINESS WIRE)–

Industrial Nanotech, Inc. (Pink Sheets:INTK), an emerging global leader in nanotechnology based energy saving and sustainable solutions announced today that the Company is opening a Corporate Sales Office in India with the next 4-6 weeks. Industrial Nanotech, Inc. has seen significantly increased demand in India for their Nansulate energy saving and protective coatings from OEM manufacturers as well as end manufacturing users to reduce energy costs. The company plans to establish an office first in Southern India, in or near Bangalore, with expansion to Northern India and Western India in the near future.

India has become an increasingly important country as their manufacturing sectors and economy as a whole continue to have a healthy growth rate, stated Francesca Crolley, VP of Business Development for Industrial Nanotech, Inc. We began a strategy this year focused on boosting our marketing and brand presence in India as an energy saving solution and it has returned significant results. These include multiple inquiries from manufacturers that want to use Nansulate coatings for insulation of their equipment for energy savings and surface temperature reduction, as well as a meeting with a leading OEM manufacturer of process cooling systems with 14 locations throughout India, and an international client base, that is interested in incorporating our technology into the process cooling systems they manufacture and sell. We have seen our marketing, which was focused on commercial and industrial, bring in sales and inquiries from multiple markets and at such a response level that it was obvious to us that setting up an Industrial Nanotech, Inc. office in India, staffed by a sales and technical support team which we hire and train, was the logical next step. The availability of a well educated workforce with an excellent work ethic presents a tremendous opportunity for the Company and will allow us to both accommodate factory visit requests from around the country with our own technical teams, as we do in the US, and the ability to more rapidly service and grow this vital market.

India’s economic growth is expected to remain robust in 2012 and 2013, despite likely headwind of double-dip recessions in Europe and the US, according to a United Nations’ annual economic report – World Economic Situation and Prospects 2012. The Indian economy is expected to grow between 7.7 per cent and 7.9 per cent this year, as per the report. India is the second most preferred destination for foreign investors, according to the report ‘Doing Business in India’ by Ernst & Young. The report explores India’s key sectors, investment climate, funding scenario, laws and regulations, to aid companies that are doing, or plan to do business in India.

About Nansulate

Nansulate is the Company’s patented product line of award winning, specialty coatings containing a nanotechnology based material and which are well-documented to provide the combined performance qualities of thermal insulation, corrosion prevention, resistance to mold growth, fire resistance, chemical resistance and lead encapsulation in an environmentally safe, water-based, coating formulation. The Nansulate Product Line includes industrial, residential, agricultural and solar thermal insulation coatings. Additional information about the Company and its products can be found at their websites, (www.inanotk.com) and (www.nansulate.com). Blog: www.nansulate.com/nanoblog, Twitter: www.twitter.com/NanoPioneer, Facebook: www.facebook.com/Nansulate.

About Industrial Nanotech Inc.

Industrial Nanotech Inc. is a global nanoscience solutions and research leader and member of the U.S. Green Building Council. The Company develops and commercializes new and innovative applications for sustainable nanotechnology which are sold worldwide.

Safe Harbor Statement

Safe Harbor Statement under the Private Securities Litigation Reform Act of 1995: This release includes forward-looking statements made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995 that involve risks and uncertainties including, but not limited to, the impact of competitive products, the ability to meet customer demand, the ability to manage growth, acquisitions of technology, equipment, or human resources, the effect of economic and business conditions, and the ability to attract and retain skilled personnel. The Company is not obligated to revise or update any forward-looking statements in order to reflect events or circumstances that may arise after the date of this release.

Follow this link:
Industrial Nanotech, Inc. Announces Expansion to India with Corporate Sales Office

PNNL honored for nanotechnology to help sailors

A nanotechnology system that will allow sailors on Navy submarines to breathe easy has won Pacific Northwest National Laboratory a national award.

The 2012 Federal Laboratory Consortium Interagency Partnership Award was given to the Department of Energy national lab in Richland.

Researchers created a system that captures carbon dioxide directly from the air within a submarine to improve air quality, while providing a more environmentally friendly removal process.

The technology — self assembled monolayers on mesoporous supports or SAMMS — can be used to replace a system relied on for more than half a century by the U.S. Navy and many other countries.

The current system is a bulky, heavy, corrosive and malodorous liquid process that produces a significant amount of organic solvent waste, according to PNNL.

“This is a new application of a technology that was previously developed by PNNL to remove heavy metal contamination from ground and surface waters found at many DOE waste sites,” PNNL material scientist Glen Fryxell, one of the key inventors of the SAMMS technology, said in a statement.

The SAMMS materials can absorb large quantities of liquid and airborne contaminants without creating secondary waste and can be disposed of as nonhazardous waste.

The SAMMS technology is based on a new class of hybrid nanoporous materials that can rapidly capture contaminants such as carbon dioxide, mercury or arsenic directly from the atmosphere or liquid environments.

For air rejuvenation systems, SAMMS can provide a controlled release of the carbon dioxide using a gentle application of heat or vacuum, according to PNNL.

“The technology could open doors to other large-scale or small-scale air quality treatments,” Fryxell said.

Original post:
PNNL honored for nanotechnology to help sailors

Nanoparticles may pose environmental threat

(ISNS) — No longer the stuff of science fiction, nanoparticles are becoming more and more common. The extremely tiny objects can do just about everything, from filtering pollution to delivering medicine in the body. However, no one is sure of the effects if they get loose in the environment.

A team of scientists from the National Institute of Standards and Technology and the University of Massachusetts at Amherst thinks there may be something to worry about.

They have not proven the particles are dangerous, but have shown that some nanoparticles can be absorbed into plants and mutate the plant’s DNA, and that, they say, is worth a further look.

Nanoparticles are so small that they act as a bridge between the size of atoms and something of tangible substance. The thickness of a human hair is measured in millionths of a meter; nanoparticles, in billionths of a meter.

And now, they are everywhere. Manufacturers put them in clothing such as socks to kill bacteria. They are in a type of house paint that cleans itself in sunlight and in the coating on eyeglasses. Clear sunscreen lotion now on the market contains zinc or titanium nanoparticles. Cars will soon have paint that heals itself from scratches.

Nanoparticles have become so common it is assumed inevitably they will end up in the environment.

To see what would happen to plants exposed to nanoparticles, the researchers took particles of copper oxide and exposed three kinds of plants to them: radishes and two types of rye, the researchers reported in Environmental Science & Technology.

They chose nanoparticles of copper because they are widely used for coloring glass, in ceramics, as a polish and in the manufacturing of rayon. They also are used in the electronics industry to manufacture semiconductors, said Bryant Nelson of the National Institute of Standards and Technology.

The research team also used particles of copper oxide larger than nano-size as a comparison as well as regular copper ions.

Copper oxide is an oxidizing agent, and some oxidizing agents from metals can cause cancer in humans, a reason for the concern.

Continued here:
Nanoparticles may pose environmental threat

Global Nanobiotechnology Industry

NEW YORK, May 16, 2012 /PRNewswire/ — Reportlinker.com announces that a new market research report is available in its catalogue:

http://www.reportlinker.com/p0181059/Global-Nanobiotechnology-Industry.html#utm_source=prnewswire&utm_medium=pr&utm_campaign=Nanotechn

This report analyzes the worldwide markets for Nanobiotechnology in US$ Million by the following Technology Segments: Nanomaterials (Solid Inorganic Nanoparticles, Nanocomposites, Nanostructured Materials & Membranes, Nanotubes and Fullerenes, & Other Nanomaterials), and Nanodevices/Tools. The report provides separate comprehensive analytics for the US, Japan, Europe, and Rest of World. Annual forecasts are provided for each region for the period of 2009 through 2017. Also, a six-year historic analysis is provided for these markets. The report profiles 117 companies including many key and niche players worldwide such as Aduro BioTech, Arrowhead Research Corporation, Calando Pharmaceuticals, Inc., Agilent Technologies Inc., Asklepios BioPharmaceutical Inc., Biosante Phosphate Pharmaceuticals, Inc., Celgene Corporation, Elan Pharmaceuticals, Elitech Group, Flamel Technologies, Inc., Gilead Sciences Inc., Life Technologies Corporation, NanoBio Corporation, Nanogen, Inc., Nanophase Technologies Corporation, pSivida Ltd., Sigma Aldrich Company, Starpharma Holdings Ltd., Dendritic Nanotechnologies, Inc., SkyePharma Pharmaceuticals, Unidym, Inc., and Zyvex Instruments LLC. Market data and analytics are derived from primary and secondary research. Company profiles are primarily based upon search engine sources in the public domain.

I. INTRODUCTION, METHODOLOGY & PRODUCT DEFINITIONSStudy Reliability and Reporting Limitations I-1Disclaimers I-2Data Interpretation & Reporting Level I-3Quantitative Techniques & Analytics I-3Product Definitions and Scope of Study I-31. Nanomaterials I-4Solid Inorganic Nanoparticles I-4Nanocomposites I-4Nanostructured Materials and Membranes I-4Nanotubes and Fullerenes I-4Other Nanomaterials I-4Nanoshells I-4Nanohorns I-5Nanocapsules I-52. Nanodevices/Tools I-5II. EXECUTIVE SUMMARY

1. INDUSTRY OVERVIEW II-1

A Curtain Raiser II-1

Nanobiotechnology – The Next Big Thing II-2

Nanotechnology & Biology Tie the Knot: “Two to Tango” II-4

Where Conventional Molecular Science Falls Short Nanobio

Steps In II-4

Excerpt from:
Global Nanobiotechnology Industry

A Queens College Student Goes From Boilers to Dartmouth Medical School

Log in to manage your products and services from The New York Times and the International Herald Tribune.

Don’t have an account yet? Create an account

E-Mail or Member ID

Password

Remember Me Log In

Read the original here:
A Queens College Student Goes From Boilers to Dartmouth Medical School

"How To Get Into Medical School With A Low GPA" eBook by Harvard MD and Admissions Consultant Officially Launches

After a successful recent pre-launch, the acclaimed new eBook How To Get Into Medical School With A Low GPA by Dr. Suzanne M. Miller has been touted as a lifeline for pre-meds who refuse to give up on their dream of becoming a doctor due to a low GPA.Washington, DC (PRWEB) May 16, 2012 With the recent launch of her new eBook, How To Get Into Medical School With A Low GPA, Dr. Miller tackles one …

Read more here:
"How To Get Into Medical School With A Low GPA" eBook by Harvard MD and Admissions Consultant Officially Launches